APEX1 and non-small cell lung carcinoma: concluded that APE1 is a poor prognosis marker in NSCLC, and the suppression of APE1 with the APE1 inhibitor NO.0449-0145 could promote the accumulation of unrepaired DNA damage in NSCLC cells continuously and induce DNA damage, apoptosis, pyroptosis, and necroptosis in vitro and in vivo, as well as overcome both DDP- and erlotinib-resistance in NSCLC.